Increased airway hyperresponsiveness and epithelial remodeling in asthmatic LTA 4 H-KO mice may be mediated by CysLTs rather than elevated tripeptide PGP.
The recent article by Patel et al. (1) characterizes the biological response of an allergic pulmonary inflammation on the background of leukotriene A 4 hydrolase (LTA 4 H)-deficient mice. The authors demonstrate that, although many parameters of inflammation were reduced in the absence of LTA 4 H, the mice exhibited increased airway resistance, airway remodeling, and goblet cell activation.
Work from this group previously suggested that accumulation of the tripeptide proline-glycine-proline (PGP) in the absence of LTA 4 H would lead to enhanced neutrophilic inflammation in models of pulmonary infection (2, 3) ; in this model of sterile allergic inflammation, however, no such enhanced neutrophilic inflammation could be observed. Our recent publication demonstrated that PGP is actually not chemotactic for neutrophils in LTA 4 H knockout (KO) mice nor in human cells and provides an explanation for the observations by Patel et al. on neutrophils in this sterile inflammatory setting (4). Therefore, our conclusion was that the enhanced neutrophil response previously observed in infection models is likely a compensatory immune response to the infection in the absence of LTA 4 H rather than driven by PGP elevation.
Similarly, we believe that the observations on airway hyperresponsiveness and epithelial remodeling in this recent article by Patel et al. may not be due to the elevation of the PGP peptide but could actually be caused by the effects of the cysteinyl leukotrienes (CysLTs) in asthma, which are known to induce bronchoconstriction, airway remodeling, goblet cell activation, and mucus production (5). It is well known that inhibition of specific enzymes of the arachidonic acid pathway can lead to the elevation of lipid mediators due to pathway shunting. We have observed that absence of LTA 4 H can lead to the elevation of CysLTs after stimulation of immune cells in vitro or in inflammatory settings in vivo in LTA 4 H KO mice (Fig. 1) . It is tempting to speculate that the same may have also occurred in the experimental setting used by Patel et al., particularly because this was observed even clinically with the LTA 4 H inhibitor JNJ40929837 by Johnson & Johnson in an asthma clinical trial (6) .
The authors did not detect elevated CysLTs in house dust mite (HDM)-challenged LTA 4 H KO mice (1). However, this measurement was performed 24 hours after allergen challenge. CysLTs are released very rapidly after allergen challenge and become less abundant thereafter (7) . Hence, the elevation of CysLTs may have been missed by just assessing one single timepoint after the challenge.
To demonstrate that the observed effect on airway resistance, airway remodeling, and goblet cell activation is actually due to PGP and not due to the well-known effects of CysLTs, the authors should have demonstrated that the effect can also be seen in LTA 4 H KO mice that were treated with the CysLT receptor antagonist Montelukast or more ideally a 5-lipoxygenase inhibitor. The latter would allow for the study of elevated PGP without the simultaneous elevation of CysLTs in LTA 4 H KO mice.
Although the authors demonstrate that PGP is elevated in bronchoalveolar lavage fluid of LTA 4 H KO mice after allergen challenge (1), they never demonstrate that acetyl-PGP is also elevated. In the paper, it is assumed that PGP gets converted into acetyl-PGP in vivo and that this will have similar effects to PGP. However, because this was not directly shown, we question the use of acetyl-PGP as a surrogate to demonstrate the role of PGP. Indeed, taking into account that acetyl-PGP is not degraded by LTA 4 H and that knocking out LTA 4 H in mice does not influence its abundance (4), the observation that this peptide is not detected in the epithelium of HDM-stimulated mice further validates this concern.
Furthermore, we believe that using the l-arginine-threonine-arginine (RTR) peptide as an antagonist to revert the effects of acetyl-PGP is not an appropriate control either because it has been shown previously that RTR also interferes with the action of other immune mediators signaling via CXCR1 and CXCR2 such as IL-8 (interleukin-8) (8) . Hence, any observed immune modulation using this peptide will be a result of polypharmacology and, without additional controls, cannot be deconvoluted into a single pathway, particularly given the fact that acetyl-PGP is not even detectable in HDM-stimulated LTA 4 H KO mice.
The authors suggest that the failures of LTA 4 H inhibitors in the clinic may be due to PGP elevation. We believe that this conclusion is unsubstantiated, as to our knowledge, so far, only two LTA 4 H inhibitors were tested in clinical efficacy trials in patients. The first, compound JNJ40929837 by Johnson & Johnson, was tested in an asthma trial and showed lack of efficacy (6) . In this study, it was clinically demonstrated that CysLTs were elevated by LTA 4 H inhibition, providing a possible reason for the lack of efficacy because CysLTs are among the main pathological drivers in asthma. The second, compound Acebilustat from Celtaxsys, was tested in cystic fibrosis (CF) and demonstrated a reduction in markers of neutrophilic inflammation (9) , as well as a clinically meaningful reduction in inflammatory exacerbations in a 48-week phase 2b study (http://www. celtaxsys.com/2018/08/02/celtaxsys-announces-results-of-phase-2-trial-showing-clinically-meaningful-improvement-in-pulmonaryexacerbations-in-cystic-fibrosis-patients/). Although it was previously demonstrated that the levels of PGP are elevated in CF (10) 
